Towa Pharmaceutical Co (TWAPF) Financial Statements
Towa Pharmaceutical Co Financial Overview
Towa Pharmaceutical Co's market cap is currently $1.10B. The company's EPS TTM is $419.38; its P/E ratio is 21.14; and it has a dividend yield of 1.95%. Towa Pharmaceutical Co is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $0.64. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 259.59B | $ 273.71B | $ 227.93B | $ 208.86B | $ 165.62B |
| Gross Profit | $ 94.73B | $ 99.10B | $ 81.38B | $ 72.71B | $ 70.19B |
| Operating Income | $ 23.24B | $ 23.10B | $ 17.65B | $ 5.51B | $ 18.54B |
| EBITDA | $ 48.06B | $ 38.26B | $ 43.29B | $ 25.14B | $ 33.43B |
| Net Income | $ 18.99B | $ 5.25B | $ 16.17B | $ 2.20B | $ 15.91B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 45.47B | $ 45.31B | $ 29.65B | $ 24.26B | $ 32.83B |
| Total Assets | $ 470.82B | $ 475.29B | $ 430.65B | $ 371.35B | $ 332.10B |
| Total Debt | $ 230.98B | $ 226.74B | $ 202.36B | $ 161.52B | $ 140.70B |
| Net Debt | $ 185.51B | $ 181.43B | $ 172.71B | $ 137.26B | $ 107.87B |
| Total Liabilities | $ 299.19B | $ 297.18B | $ 274.76B | $ 234.45B | $ 199.93B |
| Stockholders' Equity | $ 171.63B | $ 178.10B | $ 155.89B | $ 136.89B | $ 132.17B |
| Cash Flow | |||||
| Free Cash Flow | $ -5.33B | $ 8.15B | $ -29.64B | $ -26.19B | $ 10.99B |
| Operating Cash Flow | $ 23.40B | $ 30.43B | $ 8.21B | $ 2.54B | $ 22.13B |
| Investing Cash Flow | $ -31.29B | $ -25.66B | $ -40.39B | $ -30.28B | $ -59.73B |
| Financing Cash Flow | $ 21.57B | $ -6.83B | $ 35.41B | $ 17.48B | $ 46.54B |
Currency in JPY
